Materion Implements Stature from Dyadem for Quality Risk Management
Dyadem today announced that it has been selected by Materion (NYSE: MTRN) to provide Quality Risk Management software solutions to support its commitment to superior product quality. Materion will use Dyadem’s Stature software to gain more visibility between departments and to more efficiently manage its quality risk assessment efforts, improve its process controls and to manage overall product quality.
Stature is being deployed at Materion's Advanced Materials Technologies & Services (AMTS) business, an advanced materials products and services company that manufactures and produces everything from specialty metals and precision optical filters to inorganic chemicals and powders. Previously, Materion had been using a non-specialized spreadsheet software program to conduct risk assessments. As part of a global project initiated in 2010 to improve its process controls across all of its manufacturing operations, Materion has implemented Stature, and is now able to consolidate and standardize all risk assessments across departments, ensuring shared corporate knowledge and the capture of best practices and lessons learned. The focus for Materion’s global quality project is the development of several key quality tools, including Process Maps, FMEAs and Control Plans. Stature will enable Materion to develop these tools in a standardized format using a common application.
"As our organization moves forward in improving our Quality Systems through the use of tools such as Failure Modes & Effects Analysis (FMEA), Dyadem software solutions will allow us to implement these tools more efficiently,” said Matthew Rigerman, Director of Quality, Materion AMTS. “Stature allows our team to share information across our product lines and production facilities, ensuring that lessons learned are communicated across our entire organization."
Stature, Dyadem’s enterprise risk management software solution, will help Materion conduct more efficient Design and Process FMEAs, and share information from one study to the next and across users. Stature is a Web-based enterprise risk and quality management system that links disconnected risk management processes across the organization. By helping companies identify and mitigate risks across a global organization, Stature enables companies to increase their operational effectiveness, comply with industry regulations and bring better quality products to market. Ensuring continuous communication and transparency throughout a program, project or process, Stature provides key performance indicators and visibility into an organization's top risks. With access to data from across risk assessments, knowledge libraries and managed through standardized templates, Stature will serve as the system of record for quality while ensuring corporate consistency across all past, present and future quality studies.
“The manufacturing industry as a whole faces a multitude of risks, in both engineering and production, and from across the entire supply chain," said Kevin North , President and CEO, Dyadem. “With Stature, Materion is not only proving its commitment to product quality, but also its commitment to its stakeholders. With better visualization of quality risks, Materion will be able to identify potential issues early in the product lifecycle, and will be able to reduce the likelihood of bringing defective products to the market.”
About Dyadem
Dyadem is the market leader in Operational Risk Management and Quality Risk Management solutions. Dyadem provides software and services that empower companies to discover and manage the risks to people and products in the design and manufacturing processes. Dyadem helps some of the world’s largest companies achieve regulatory compliance and business continuity, serving the Oil & Gas, Chemical, Mining, Pharmaceutical, Medical, Automotive, Electronics and Aerospace and Defense industries. For more information, visit www.dyadem.com .
About Materion
Brush Engineered Materials Inc. has officially changed its name to Materion Corporation and unified all of its businesses under the new Materion brand, Effective March 8, 2011. Based in Cleveland, Ohio, Materion is a leading global producer of advanced materials and services providing enabling technology solutions for customers in the fastest growing segments of long-term global growth markets including consumer electronics, defense and science, industrial components and commercial aerospace, energy, automotive electronics, telecommunications infrastructure, medical and appliance. It is traded on the New York Stock Exchange under the symbol: MTRN.
Materion Advanced Materials Technologies & Services, based in Buffalo, New York, manufactures and sells precious, non-precious, specialty metals; inorganic materials; specialty coatings and electronic packaging. For more information, visit www.materion.com .
Contact:
Dyadem
Maureen Robusto,
+1 978-289-7752
Manager, Public
Relations
mrobusto (at
) dyadem (dot
) com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom